Tuberculosis vaccine

Tuberculosis Vaccine

Tuberculosis (TB) is a potentially serious infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs, but it can also impact other parts of the body. The development of a vaccine against tuberculosis has been a significant milestone in combating this disease. The most commonly used vaccine for TB is the Bacillus Calmette-Guérin (BCG) vaccine.

Bacillus Calmette-Guérin (BCG)

The BCG vaccine is the only vaccine currently available for the prevention of tuberculosis. It is named after the French scientists Albert Calmette and Camille Guérin, who developed the vaccine in the early 20th century. The vaccine is prepared from a strain of the attenuated (weakened) live bovine tuberculosis bacillus, Mycobacterium bovis, which has lost its virulence in humans by being specially cultured in a substrate for years.

Efficacy

The efficacy of the BCG vaccine varies significantly based on geographical location and the population being vaccinated. It is most effective in preventing severe forms of TB, such as tuberculous meningitis in children. However, its effectiveness in preventing pulmonary TB in adults is more variable and less consistent.

Administration

The BCG vaccine is typically administered to infants as a single intradermal injection in the upper arm. The World Health Organization (WHO) recommends that all infants in countries with a high prevalence of TB or with a high maternal HIV rate receive the BCG vaccine as close to birth as possible.

Side Effects

Side effects of the BCG vaccine are generally mild and can include swelling at the injection site, mild fever, and, in rare cases, more severe complications such as osteitis.

Other TB Vaccines

Research into developing new vaccines for tuberculosis is ongoing. Several potential vaccines are in various stages of development and clinical trials. These include subunit vaccines, viral vector vaccines, and whole-cell vaccines. The goal of these new vaccines is to improve efficacy, especially in TB-endemic regions, and to offer protection against TB in adults, where the BCG vaccine is less effective.

Challenges in TB Vaccine Development

Developing a new TB vaccine faces several challenges. These include the complex nature of Mycobacterium tuberculosis itself, the need for a better understanding of the immune responses required for protection, and the requirement for long and expensive clinical trials to test vaccine efficacy and safety.

Conclusion

The BCG vaccine remains a critical tool in the fight against tuberculosis, especially in protecting children in TB-endemic regions. However, the development of new and more effective vaccines is essential to control and eventually eliminate TB as a public health threat.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian